97%(195)190 out of 195 people found this document helpful
This preview shows page 17 - 19 out of 19 pages.
The methods of the research involved greater than 60 experts in the field of STI, infectious disease, epidemiology, and medicine defining the most current developments of STI clinical and preventative services. A number of nine questions were presented to address the treatment of gonorrhea. A PubMed search of articles since 2008 to 2013 written in English. Data published from websites internationally public health agencies and from GISP (surveillance of 25-30 cities in the United States) were utilized. The nine proposed questions revealed that acceptable treatment of gonorrhea with dual therapy of ceftriaxone 250mg intramuscularly as a one time dose and azithromycin 1 g orally as a one time dose in uncomplicated gonorrhea of the urethra, cervix, rectum, or pharynx is sufficient at this time. For the treatment of urethral, cervical, and rectal infections the dual treatment with cefixime 400mg orally once with azithromycin 1 g orally once can be used alternately when ceftriaxone is unavailable. The monotherapy of azithromycin 2g orally is no longer a recommendation. The investigation of new treatment regimens is urgently needed as a result of susceptibility to antimicrobial resistance. How did the study support Ms. Campbell’s case: The article is relevant to the patient’s treatment which is impacted by the clinicians understanding of always observing for current treatment guideline due to the changing of treatment regimen as a result of antibiotic resistance.
EVIDENCE-BASED ARTICLES cont.Title, author, and year of article: Cervicitis: A prospective observational study of empiric azithromycin treatment in women with cervicitis and nonspecific cervicitis. Lusk, M. J., Garden, F. L., Cumming, R. G., Rawlinson, W. D., Naing, Z. W., & Konecny, P. (2017). Brief summary/purpose of the study: The article evaluates the treatment of cervicitis with azithromycin 1 g. The study was conducted in Sydney, Australia. The initially started out with 1,327 participants 67 were ineligible 72 declined 630 were actually eligible ultimately 558 were enrolled in the study. The study used a total of 116 actual participants. The applicants were placed into two overlapping groups known as cervicitis group one with 116 members and cervicitis group two (non-specific cervicitis) with 96 applicants. The following groups were omitted women that had Neisseria gonorrhea, Chlamydia trachomatis, and Mycoplasma genitalium. To test for the chlamydia, mycoplasma genitalium and trichomonas was done by PCR and Neisseria gonorrhea by PCR and culture. The outcome to treatment was for cervicitis or other reported vaginal symptoms. In cervicitis group one azithromycin reduced cervicitis at follow-up in 23 out of 116 of the member with the prevalence of chlamydia and mycoplasma genitalium. No effect noted with the treatment of azithromycin in patient’s in the cervicitis group two. The treatment did not reduce symptoms associated with vaginal complaints. The study demonstrates that azithromycin 1 g is effective at reducing cervicitis in populations with high prevalence of chlamydia and mycoplasma genitalium.